Review
Research progress of anti-Müllerian hormone in female reproductive outcomes
He Yichen, Wu Yanting, Huang Hefeng
Published 2020-09-25
Cite as Chin J Reprod Contracep, 2020, 40(9): 767-772. DOI: 10.3760/cma.j.cn101441-20200522-00300
Abstract
Anti-Müllerian hormone (AMH) is a dimeric glycoprotein and a member of the transforming growth factor-beta (TGF-β) family. It has been more than 17 years since the measurement of serum AMH as a biomarker first allowed the quantitative assessment of ovarian reserve. Meanwhile, the implication of AMH has been expanding. AMH regulates follicular development in the ovary and also plays an important neuroendocrine role outside the gonads. There are certain associations between AMH and reproductive outcomes such as miscarriage, live birth, preterm birth and hypertensive disorders in pregnancy. This article reviews the latest research progress of AMH in association with reproductive outcomes, with a view to provide a reference for the clinical work of obstetrics and gynecology.
Key words:
Anti-Müllerian hormone; Female reproduction; Reproductive technology, assisted; Reproductive physiology; Adverse reproductive outcomes
Contributor Information
He Yichen
Department of Reproductive Medicine, International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Embryo Original Diseases,Shanghai 200030, China
Wu Yanting
Department of Research and Education, International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
Huang Hefeng
Department of Reproductive Medicine, International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Embryo Original Diseases,Shanghai 200030, China